| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Lenzilumab (anti-GM-CSF)
CAS:1229575-09-0
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K13664
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Lenzilumab
CAS:1229575-09-0
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Lenzilumab
CAS:1229575-09-0
Purity:95% Package:1mg;1g;100g
|
Lenzilumab manufacturers
- Lenzilumab
-
- $183.00 / 1mg
-
2026-01-28
- CAS:1229575-09-0
- Min. Order:
- Purity: 95.00%
- Supply Ability: 10g
|
| | Lenzilumab Basic information |
| Product Name: | Lenzilumab | | Synonyms: | Lenzilumab;Research Grade Lenzilumab(DHC06703);Research Grade Lenzilumab;Lenzilumab (anti-GM-CSF) | | CAS: | 1229575-09-0 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Lenzilumab Structure]() |
| | Lenzilumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Lenzilumab Usage And Synthesis |
| Uses | Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies[1][2]. | | in vivo | Lenzilumab (i.p., 10 mg/kg, daily, 10 days) inhibits GM-CSF without inhibiting the cellular function of CAR-T and enhances its antitumor activity in NSG mice[1].
| Animal Model: | NSG mice with CART19 cells[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection; daily; 10 days | | Result: | Neutralized GM-CSF, had antitumor activity and improved the proliferation of cytokine release syndrome (CRS) and neuroinflammation (NI). |
| | References | [1] Rosalie M Sterner, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019 Feb 14;133(7):697-709. DOI:10.1182/blood-2018-10-881722
[2] Zelalem Temesgen, et al. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study. Mayo Clin Proc. 2020 Nov;95(11):2382-2394. DOI:10.1016/j.mayocp.2020.08.038 |
| | Lenzilumab Preparation Products And Raw materials |
|